Hawaii SB967 mandates insurance coverage for intravenous ketamine therapy to treat treatment-resistant depression.

Hawaii SB967 requires Medicaid and private insurance to cover intravenous ketamine therapy for treatment-resistant depression, aiming to make this treatment more accessible. The bill allocates state funds to Medicaid to facilitate this coverage. It mandates that insurance policies issued or renewed after January 1, 2026, cover a percentage of the costs for this therapy, as determined by licensed medical professionals. The bill also notes the higher cost of this treatment compared to alternatives and its potential benefits in increasing neuroplasticity.

Hawaii SB967 mandates insurance coverage for intravenous ketamine therapy to treat treatment-resistant depression.

Hawaii SB967 requires Medicaid and private insurance to cover intravenous ketamine therapy for treatment-resistant depression, aiming to make this treatment more accessible. The bill allocates state funds to Medicaid to facilitate this coverage. It mandates that insurance policies issued or renewed after January 1, 2026, cover a percentage of the costs for this therapy, as determined by licensed medical professionals. The bill also notes the higher cost of this treatment compared to alternatives and its potential benefits in increasing neuroplasticity.